The gap is in media coverage, not in evidence
and if FDA wants to add a substance to the bulks list, it generally has to go through notice-and-comment rulemaking
Meanwhile, a copper peptide known as GHK-Cu (glycyl-L-histidyl-L-lysine-copper) has been studied since the 1970s keeps showing up as a legitimate alternative
Patients who choose oral tirzepatide should do so under medical supervision with a clear understanding that compounded formulations have less clinical data than FDA-approved injections
Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing